Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 451-456

  Meyer, D ^a   Fressinaud, E ^a   Gaucher, C ^b   Lavergne, J M ^a   Hilbert, L ^b   Ribba, A S ^a   Jorieux, S ^b   Mazurier, C ^b  

^a BICÊTRE HOSPITAL   (France)

^b LFB Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CONFERENCE PAPER; GENE MUTATION; GENE STRUCTURE; GENETIC HETEROGENEITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN VARIANT; STRUCTURE ACTIVITY RELATION; VON WILLEBRAND DISEASE;

EID: 0030836531     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657568     Document Type: Conference Paper

References (30)

1. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67:594-9.
2. Meyer D, Girma JP. von Willebrand factor - structure and function. Thromb Haemost 1993; 70:99-104.
3. Ginsburg D, Sadler JE. von Willebrand disease - a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69:177-84.
4. Mazurier C, Meyer D. Molecular basis of von Willebrand disease. In : Baillière's Clinical Haematology, Lee CA (ed). Baillière Tindall, London 1996; pp 229-41.
5. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71:520-5.
6. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease - Results of an international survey. Thromb Haemost 1996; 76:270-4.
7. Gu J, Jorieux S, Lavergne JM, Ruan C, Mazurier C, Meyer D. A patient with type 2N von Willebrand disease is heterozygous for a new mutation : Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. Blood 1997; (in press).
8. Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996; 87:1013-21.
9. Miyata S, Goto S, Federici AB, Ware J, Ruggeri ZM. Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Iba. J Biol Chem 1996; 271:9041-53.
10. Gaucher C, De Romeuf C, Rauis-Morret M, Corazza F, Fondu P, Mazurier C. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor. Thromb Haemost 1995; 73:610-6.
11. Ruggeri ZM, Zimmerman TS. von Willebrand Factor and von Willebrand disease. Blood 1987; 70:895-904.
12. Casonato A, Gemmati D, Lunghi B, Bizzano N, Girolami A, Verzola I, Bernardi F. Increased susceptibility to proteases in type 2A von Willebrand disease associated with two novel mutations (Val867Glu, Pro864His). Thromb Haemost 1995; 73: 1171 (Abstr).
13. Hagiwara T, Inaba H, Yoshida S, Nagaizumi K, Arai M, Hanabusa H, Fukutake K. A novel mutation Gly1671'Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease. Thromb Haemost 1996; 76: 253-7.
14. Lavergne JM, DePaillette L, Bahnak BR, Ribba AS, Fressinaud E, Pietu G, Meyer D. Defects in type IIA von Willebrand disease : a cysteine 509 to arginine substitution in the mature von Willebrand Factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX. Br J Haemat 1992; 82: 66-72.
15. Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Pietu G. Discrepancy between IIA-phenotype and IIB-genotype in a patient with a variant of von Willebrand disease. Blood 1994; 83:833-41.
16. Holmberg L, Nilsson IM, Schneppenheim R. A new mutation in the vWF propeptide in recessive type 2A (IIC) von Willebrand disease. Haemophilia 1996; 2 supp. 1: 86 (Abstr).
17. Gaucher C, Hilbert L, Dieval J, Parquet A, Mazurier C. The transient expression of two phenotype IIC candidate mutations confirms the importance of vWF propeptide in the multimerization process. Thromb Haemost 1995; 73: 1168 (Abstr).
18. Gaucher C, Mazurier C. Phenotype IIC von Willebrand disease: the expression of three mutant recombinant von Willebrand factors (vWF) confirms the importance of the D2 domain of vWF propeptide in the multimer assembly process. Br J Haematol 1996; 93: 15 (Abstr).
19. Schneppenheim R, Brassard J, Krey S, Budde U, Kunicki TJ, Holmberg L, Ware J, Ruggeri ZM. Defective dimerization of von Willebrand factor subunits due to a Cys'Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 93:3581-6.
20. Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M:Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 1996; 88:2559-68.
21. Jorieux S, Gaucher C, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor abolishes the factor VIII binding and affects the multimerization. Haemophilia 1996; 2 supp. 1 : 86 (Abstr.).
22. Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib - Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 1995; 270:13406-14.
23. Inbal A, Kornbrot N, Harrison P, Randi AM, Sadler JE. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding studies with recombinant von Willebrand factor. Thromb Haemost 1993; 70:1058-62.
24. Siguret V, Ribba AS, Christophe O, Cherel G, Oben B, Rouault C, Nishikubo T, Meyer D, Girma JP, Pietu G. Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695. Thromb Haemost 1996; 76:453-9.
25. Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE. Von Willebrand disease type B : A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846-9.
26. Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF. Blood 1995;86:1010-8.
27. Gaucher C, Hilbert L, Meriane F, Mazurier C, Pernod G. Type 2 von Willebrand disease resulting from an insertion or deletion in the 509-695 disulphide loop of von Willebrand factor. Thromb Haemost. 1995; 73: 1168 (Abstr).
28. Hilbert L, Gaucher C, de Romeuf C, Parquet A, Abgrall JF, Trzeciak C, Mazurier C. Identification of "new" type 2B von Willebrand disease mutations : R543Q, R545P and R578L. Br J Haematol 1996; 93: 310 (Abstr).
29. Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 1996; 35:13460-8.
30. Marti T, Rösselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 1987; 26: 8099-109.